Results 61 to 70 of about 569,881 (316)

PICALM::MLLT10 translocated leukemia

FEBS Letters, EarlyView.
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen, Antonia C. Nakatsugawa, Natalie Barton, Henry Haines, Gary S. Stein, Janet L. Stein, Daniel S. Wechsler, Jessica L. Heath   +7 more
wiley   +1 more source

Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity

Haematologica, 2008
Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell ...
Désirée Bonci, Maria Musumeci, Valeria Coppola, Antonio Addario, Concetta Conticello, Michael Hahne, Massimo Gulisano, Francesco Grignani, Ruggero De Maria   +8 more
doaj   +1 more source

Targeting self-renewal pathways in myeloid malignancies [PDF]

, 2013
A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core   +2 more sources

Treatment of Relapsed Acute Myeloid Leukemia

Current Treatment Options in Oncology, 2020
Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40–50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse
F. Thol, A. Ganser
semanticscholar   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage

Frontiers in Oncology, 2021
Acute leukemia of ambiguous lineage (ALAL) is a rare type of leukemia and represents an unmet clinical need. In fact, due to heterogeneity, substantial rarity and absence of clinical trials, there are no therapeutic guidelines available.
Gabriele Merati, Marianna Rossi, Anna Gallì, Elisa Roncoroni, Silvia Zibellini, Ettore Rizzo, Daniela Pietra, Cristina Picone, Barbara Rocca, Claudia Patricia Tobar Cabrera, Eleonora Gelli, Eugenio Santacroce, Luca Arcaini, Luca Arcaini, Patrizia Zappasodi   +14 more
doaj   +1 more source

Functional Genomic Landscape of Acute Myeloid Leukemia

Nature, 2018
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events.
J. Tyner, C. Tognon, D. Bottomly, Beth Wilmot, S. Kurtz, S. Savage, Nicola Long, Anna Reister Schultz, E. Traer, Melissa L. Abel, A. Agarwal, A. Blucher, U. Borate, Jade Bryant, Russell T. Burke, A. Carlos, Richie Carpenter, J. Carroll, B. Chang, Cody Coblentz, Amanda d’Almeida, R. Cook, A. Danilov, K. Dao, Michie Degnin, D. Devine, J. Dibb, David K Edwards, C. Eide, I. English, J. Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan C. Johnson, Brian Junio, A. Kaempf, Jessica T. Leonard, Chen-Jzong Lin, S. Liu, Pierrette Lo, M. Loriaux, Samuel B. Luty, T. Macey, Jason D. MacManiman, Jacqueline Martinez, M. Mori, D. Nelson, Ceilidh Nichols, Jill Peters, Justin W Ramsdill, Angela Rofelty, R. Schuff, R. Searles, E. Segerdell, Rebecca Smith, S. Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jacob P. Wagner, Kevin Watanabe-Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, C. Cogle, R. Collins, D. Connolly, M. Deininger, L. Drusbosky, C. Hourigan, C. Jordan, P. Kropf, Tara L. Lin, Micaela E. Martinez, B. Medeiros, Rachel R. Pallapati, D. Pollyea, R. Swords, J. Watts, S. Weir, D. Wiest, R. M. Winters, S. McWeeney, B. Druker   +87 more
semanticscholar   +1 more source

Immune escape and immunotherapy of acute myeloid leukemia.

Journal of Clinical Investigation, 2020
In spite of the recent approval of new promising targeted therapies, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for additional and synergistic therapeutic rationales.
L. Vago, I. Gojo
semanticscholar   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations

Haematologica, 2014
Acute myeloid leukemia is a neoplasm characterized by recurrent molecular aberrations traditionally demonstrated by cytogenetic analyses. We used high density genome-wide genotyping and gene expression profiling to reveal acquired cryptic abnormalities ...
Saman Abbas, Mathijs A. Sanders, Annelieke Zeilemaker, Wendy M.C. Geertsma-Kleinekoort, Jasper E. Koenders, Francois G. Kavelaars, Zabiollah G. Abbas, Souad Mahamoud, Isabel W.T. Chu, Remco Hoogenboezem, Justine K. Peeters, Ellen van Drunen, Janneke van Galen, H. Berna Beverloo, Bob Löwenberg, Peter J.M. Valk   +15 more
doaj   +1 more source